134 related articles for article (PubMed ID: 12686663)
1. High prevalence of fenfluramine-related aortic regurgitation in women with end-stage renal disease secondary to Chinese herb nephropathy.
Unger P; Nortier J; Muniz Martinez MC; Plein D; Vandenbossche JL; Vereerstraeten P; Vanherweghem JL
Nephrol Dial Transplant; 2003 May; 18(5):906-10. PubMed ID: 12686663
[TBL] [Abstract][Full Text] [Related]
2. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE
N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087
[TBL] [Abstract][Full Text] [Related]
3. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.
Mast ST; Jollis JG; Ryan T; Anstrom KJ; Crary JL
Ann Intern Med; 2001 Feb; 134(4):261-6. PubMed ID: 11182835
[TBL] [Abstract][Full Text] [Related]
4. Valvular heart disease and Chinese-herb nephropathy.
Van Ypersele de Strihou C
Lancet; 1998 Mar; 351(9107):991; author reply 991-2. PubMed ID: 9734973
[No Abstract] [Full Text] [Related]
5. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.
Kancherla MK; Salti HI; Mulderink TA; Parker M; Bonow RO; Mehlman DJ
Am J Cardiol; 1999 Dec; 84(11):1335-8. PubMed ID: 10614800
[TBL] [Abstract][Full Text] [Related]
6. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
Ryan DH; Bray GA; Helmcke F; Sander G; Volaufova J; Greenway F; Subramaniam P; Glancy DL
Obes Res; 1999 Jul; 7(4):313-22. PubMed ID: 10440587
[TBL] [Abstract][Full Text] [Related]
7. Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study.
Palmieri V; Arnett DK; Roman MJ; Liu JE; Bella JN; Oberman A; Kitzman DW; Hopkins PN; Morgan D; de Simone G; Devereux RB
Am J Med; 2002 Jun; 112(9):710-5. PubMed ID: 12079711
[TBL] [Abstract][Full Text] [Related]
8. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.
Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT
N Engl J Med; 1998 Sep; 339(11):725-32. PubMed ID: 9731088
[TBL] [Abstract][Full Text] [Related]
9. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.
Khan MA; Herzog CA; St Peter JV; Hartley GG; Madlon-Kay R; Dick CD; Asinger RW; Vessey JT
N Engl J Med; 1998 Sep; 339(11):713-8. PubMed ID: 9731086
[TBL] [Abstract][Full Text] [Related]
10. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities.
Jollis JG; Landolfo CK; Kisslo J; Constantine GD; Davis KD; Ryan T
Circulation; 2000 May; 101(17):2071-7. PubMed ID: 10790349
[TBL] [Abstract][Full Text] [Related]
11. Association of valvular heart disease with Chinese-herb nephropathy.
Vanherweghem JL
Lancet; 1997 Dec 20-27; 350(9094):1858. PubMed ID: 9428286
[No Abstract] [Full Text] [Related]
12. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs.
Burger AJ; Charlamb MJ; Singh S; Notarianni M; Blackburn GL; Sherman HB
Int J Cardiol; 2001 Jul; 79(2-3):159-65. PubMed ID: 11461737
[TBL] [Abstract][Full Text] [Related]
13. The longitudinal effects of fenfluramine-phentermine use.
Fleming RM; Boyd LB
Angiology; 2007; 58(3):353-9. PubMed ID: 17626991
[TBL] [Abstract][Full Text] [Related]
14. [Valvular regurgitation caused by anorectic agents].
Melero Tejedor JM; Rodríguez Bailón I; Such Martínez M; Porras Martín C; Olalla Mercadé E; Espinosa Caliani JS
Rev Esp Cardiol; 2000 Dec; 53(12):1667-70. PubMed ID: 11171493
[TBL] [Abstract][Full Text] [Related]
15. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience.
Teramae CY; Connolly HM; Grogan M; Miller FA
Mayo Clin Proc; 2000 May; 75(5):456-61. PubMed ID: 10807073
[TBL] [Abstract][Full Text] [Related]
16. Chinese herbs nephropathy presentation, natural history and fate after transplantation.
Reginster F; Jadoul M; van Ypersele de Strihou C
Nephrol Dial Transplant; 1997 Jan; 12(1):81-6. PubMed ID: 9027778
[TBL] [Abstract][Full Text] [Related]
17. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.
Hensrud DD; Connolly HM; Grogan M; Miller FA; Bailey KR; Jensen MD
Mayo Clin Proc; 1999 Dec; 74(12):1191-7. PubMed ID: 10593346
[TBL] [Abstract][Full Text] [Related]
18. Valvular heart disease associated with fenfluramine-phentermine.
Connolly HM; Crary JL; McGoon MD; Hensrud DD; Edwards BS; Edwards WD; Schaff HV
N Engl J Med; 1997 Aug; 337(9):581-8. PubMed ID: 9271479
[TBL] [Abstract][Full Text] [Related]
19. Valvular heart disease and Chinese-herb nephropathy.
Ono T; Eri M; Honda G; Kuwahara T
Lancet; 1998 Mar; 351(9107):991-2. PubMed ID: 9734974
[No Abstract] [Full Text] [Related]
20. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.
Wee CC; Phillips RS; Aurigemma G; Erban S; Kriegel G; Riley M; Douglas PS
Ann Intern Med; 1998 Dec; 129(11 Pt 1):870-4. PubMed ID: 9867728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
